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Amplification and overexpression of ErbB2 strongly
correlates with aggressive breast cancers. A deeper
understanding of pathways downstream of ErbB2 signal-
ing that are required for the transformation of human
mammary epithelial cells will identify novel strategies
for therapeutic intervention in breast cancer. Using
an inducible activation of ErbB2 autophosphorylation
qsite mutants and the MCF-10A three-dimensional (3D)
culture system, we investigated pathways used by ErbB2
to transform the epithelia. We report that ErbB2 indu-
ces cell proliferation and loss of 3D organization by
redundant mechanisms, whereas it disrupts apical basal
polarity and inhibits apoptosis using Tyr 1201 and Tyr
1226/7, respectively. Signals downstream of Tyr 1226/7
were also sufficient to confer paclitaxel resistance. The
Tyr 1226/7 binds Shc, and the knockdown of Shc blocks
the ability of ErbB2 to inhibit apoptosis and mediate
paclitaxel resistance. Tyr 1226/7 is known to activate the
Ras/Erk pathway; however, paclitaxel resistance did not
correlate with the activation of Erk or Akt, suggesting the
presence of a novel mechanism. Thus, our results show
that targeting pathways used by ErbB2 to inhibit cell
death is a better option than targeting cell proliferation
pathways. Furthermore, we identify a novel function for
Shc as a regulator of apoptosis and drug resistance in
human mammary epithelial cells transformed by ErbB2.
Oncogene (2010) 29, 174–187; doi:10.1038/onc.2009.312;
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Introduction
ErbB2/Her2/Neu is overexpressed in 25–30% of breast
cancers (Slamon et al., 1987). This overexpression
correlates with a poor clinical prognosis in node-positive
patients (Slamon et al., 1989). ErbB2-targeted therapies
such as trastuzumab, a humanized anti-ErbB2 antibody,
or Tykerb, a small molecule kinase inhibitor, are used
to treat ErbB2-positive patients. The combination of
anti-ErbB2 therapy with chemotherapeutic drugs, such
as paclitaxel or an anthracycline/cyclophosphomide
regime, shows synergistic response in controlling the
disease (Slamon et al., 2001; Romond et al., 2005).
However, only one-third of ErbB2-positive tumors
respond to trastuzumab treatment and those that do
acquire resistance within three years after the initiation
of treatment (Nahta and Esteva, 2007). The quick onset
of resistance and the presence of de novo resistance to
anti-ErbB2 therapy significantly limit the effectiveness
of currently available treatments. Thus, a deeper
understanding of the signaling pathways downstream
of ErbB2 that regulate transformation of epithelial cells
and those that block the action of cytotoxic drugs is
necessary to develop additional ways to successfully
treat women with ErbB2-positive breast cancers.
Others and we have shown that the activation of
ErbB2 transforms epithelial cells in culture by inducing
an increase cell proliferation, disrupting apical–basal cell
polarity and inhibiting apoptosis (Yu et al., 1998;
Muthuswamy et al., 2001; Yarden and Sliwkowski,
2001; Henson et al., 2006). As a receptor tyrosine kinase,
activation of ErbB2 results in the autophosphorylation
of five tyrosine sites in its cytoplasmic tail (Akiyama
et al., 1991). Four tyrosine residues, Y1144, Y1201,
Y1226/7 and Y1253, are each sufficient to transform
fibroblasts, which relates to their ability to activate Ras/
MAPK signaling pathway (Janes et al., 1994; Dankort
et al., 1997). The tyrosine at position Y1028 is a negative
regulator of transformation and mutation of this site
augments the transforming activity of ErbB2 (Dankort
et al., 1997). Although the Y1144, Y1201, Y1226/7 and
Y1253 are all redundant in their ability to transform
fibroblasts, they do differ in their transformative
potential in vivo as mice expressing Neu-Y1226/7 induce
multifocal tumors with short latency (102±22 days),
whereas Neu-Y1144 induce focal tumors after a long
latency (152±47 days) (Dankort et al., 2001b; Marone
et al., 2004). It is not clear why mutant ErbB2 receptors
harboring selected tyrosine residues differ in their ability
to induce mammary tumorigenesis. Furthermore, it is
also not clear whether the pathways activated by
autophosphorylation sites differ in their ability to
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disrupt apical–basal polarity or inhibit apoptosis.
We rationalize that investigating the mechanisms by
which ErbB2 transforms three-dimensional (3D) mam-
mary acini will provide novel insights into signaling
pathways required for ErbB2 to disrupt cell polarity and
inhibit apoptosis.
Using a combination of an inducible ErbB2 activation
system and a 3D culture system, we show that Y1144,
Y1201, Y1226/7 and Y1253 all redundantly mediate
ErbB2 signaling to promote proliferation and disrupt
organization of epithelial cells within the acinus.
However, only Y1201 was as efficient as wild type (wt)
to disrupt apical–basal polarity, and only Y1226/7 was
able to inhibit cell death during morphogenesis and in
response to treatment with the chemotherapy drug,
taxol/paclitaxel. Furthermore, we show that the signal-
ing adaptor molecule, Shc, which binds to 1226/7 was
required for ErbB2-induced inhibition of cell death,
showing that although ErbB2 uses redundant signaling
pathways to disrupt normal cell properties and induce
transformation, it uses specific pathways to disrupt cell
polarity and inhibit cell death.
Results
Generation of ErbB2 autophosphorylation mutants
that can be activated by dimerization
To investigate the effect of inducibly activating signaling
pathways downstream of each autophosphorylated
tyrosine residue in human mammary epithelial cells,
we generated a chimeric ErbB2 receptor that will
respond to a synthetic, small molecule ligand, AP1510
(herein referred to as dimerizer), but will not respond to
stimulation by epidermal growth factor (EGF) family of
ligands (Muthuswamy et al., 1999). We have previously
shown that the activation of this chimeric receptor
phenocopies wild-type ErbB2 (wtErbB2) in its ability to
transform cells and activate downstream signaling
pathways (Muthuswamy et al., 1999). This approach
has significant benefits over using cells stably over-
expressing constitutively active ErbB2, as the process of
stable selection can allow cells to adapt to constitutive
ErbB2 signaling and interfere with our ability to analyse
signals immediately downstream of ErbB2 activation.
For this study, we engineered the ErbB2 chimera to
create mutant version in which only one of the five
known autophosphorylation sites is retained as a
tyrosine and the others were mutated to phenylalanine
residues. In addition, we also generated an ErbB2
chimera that lacks all five autophosphorylation residues.
To keep nomenclature simple, we refer to the mutants
by the number that corresponds to the Tyr residue that
was not mutated (Figure 1a).
To generate populations of human mammary epithe-
lial cells that express comparable levels of the chimera
(Figure 1b), MCF-10A cells were infected with retro-
virus expressing the ErbB2 chimera and the cells were
sorted by flow cytometry using an antibody against the
p75 extracellular domain of the chimeric receptor. Three
populations of cells were collected, each expressing the
chimeric receptor at different levels. The lowest level of
expression was gated such that there was a 6% overlap
with the nonspecific signal observed in the parental
MCF-10A cells that do not express the chimeric
receptors and hence do not express the p75 receptor at
the cell surface. Pools 2 and 3 were collected at higher
levels with B2.5- and 5.0-fold increase over the
nonspecific signal observed in parental cells. The
population of cells sorted for high levels of expression
(pool 3) had constitutive activation of the receptor and
did not respond to the dimerizer, making them
unsuitable for these studies. Cells in pool 2 respond
well to ligand stimulation by an increase in receptor
tyrosine phosphorylation levels over the levels of
tyrosine phosphorylation observed in the unstimulated
state. To confirm that the cells have comparable levels of
receptor expression, we analysed monolayer cultures by
immunofluorescence analysis using anti-hemagglutinin
(HA) antibodies that recognize the tagged chimeric
receptor. The populations with medium levels of
expression had had the chimeric receptor expressed at
similar levels in every cell, suggesting that the popula-
tion will respond uniformly to receptor activation. We
determined that this expression level and the ability to
undergo dimerizer-inducible phosphorylation was stable
for 4 and 10 passages after sorting. We have limited our
experiments to cells within these passages.
To determine whether the receptor chimeras undergo
inducible phosphorylation, cells were stimulated and the
protein lysates were analysed for changes in tyrosine
phosphorylation of the chimeric receptor (Figure 1c).
Consistent with the fact that the ErbB2 mutants possess
only one of the five autophosphorylation sites, phos-
photyrosine levels in the mutants were significantly
lower than those observed for the wt receptor (compare
lanes 6, 8, 10 and 12 with lane 2). Interestingly, the
autophosphorylation sites differed in the extent to which
they were phosphorylated in response to dimerization.
Y1226/7 was phosphorylated 2.5-fold more than Y1144
and Y1201, and fivefold more than Y1253. Although it
is unclear why the sites are phosphorylated differen-
tially, it is possible that Y1226/7 is phosphorylated to a
greater level because it is comprised of two tyrosines
immediately adjacent to each other, that it is the major
phosphorylation site in ErbB2 homodimers, or that the
sites are differentially sensitive to phosphatase activity.
Further analysis will be required to differentiate between
these possibilities.
Autophosphorylation mutants transform fibroblasts
Previous studies have shown that each of the individual
tyrosine mutants, but not a mutant lacking all the five
autophosphorylated tyrosine sites, were capable of
transforming Rat1 fibroblasts when expressed within
the context of an activated form of ErbB2 (Dankort
et al., 1997). We wanted to determine whether the
autophosphorylation site mutants within the context of
our inducible chimeric ErbB2 retain the ability to
transform Rat1 fibroblasts in an inducible manner.
The wt and mutant chimeras were transiently trans-
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fected into Rat1 fibroblasts and their foci-forming
ability was assessed (Figure 2a). In the absence of
receptor activation few, if any, foci were observed.
Consistent with previous results, activation of wt and all
of the ErbB2 mutants, with the exception of phospho-
deficient mutant (YPD), induced in a significant increase
in foci formation showing that they were sufficient to
transform fibroblasts. Despite the differences in their
phoshotyrosine content, the Y1201 and Y1253 were as
potent as the wt in their ability to induce foci formation
in Rat1 fibroblasts. This suggests that the stoichiometry
of phosphorylation of these sites observed in the mutant
receptor are similar to those observed within the context
of a wt receptor. It is not clear why Y1226/7 has higher
transforming ability than the wt receptor. It might be
due to difference in levels of expression in Rat1 cells or
due to the lack of the negative regulatory site Y1028.
Nevertheless, these data show that the inducible chimeric
ErbB2 receptor phenocopies the full-length receptor in
their ability to transform Rat1 fibroblast cells.
Autophosphorylation mutants transform MCF-10A
3D acini
We have previously shown that ErbB2 activation
disrupts the 3D acini structures formed by MCF-10A
cells grown on 3D matrix cultures. Unlike the fibroblast
foci formation assay, transformation of 3D acini
involves three qualitatively different events: induction
of cell proliferation, disruption of cell polarity and
inhibition of cell death. To investigate whether the
autophosphorylated tyrosine sites differ in their
ability to regulate the events required to transform
MCF-10A 3D acini, we activated ErbB2 mutants in
Figure 1 Inducible activation of chimeric ErbB2 and the autophosphorylation site mutants. (a) Schematic of a chimeric ErbB2 with
the five autophosphorylated tyrosines present and a tyrosine phospho-deficient (YPD) mutant in which the autophosphorylation sites
have been mutated to phenylalanine. The black and white speckled bars represent the extracellular and transmembrane domains of the
low-affinity NGFR p75 receptor. The bars with black slashes represent the ErbB2 intracellular domain. The lines emanating from this
domain mark the sites of the autophosphorylated tyrosines. Circles atop these lines indicate a tyrosine, their absence indicates a
mutation of the tyrosine to alanine. Black bars represent the FKBP domains. The small terminal box represents the hemagglutinin
(HA) tag (b) MCF-10As were infected with retrovirus encoding chimeric ErbB2 and the mutants. The cells were then bead selected and
subsequently subjected to fluorescence-activated cell sorting to obtain comparable levels of expression. A western blot shows
expression levels of pool 2, which was used for subsequent analysis. (c) Western blot carried out with phospho-tyrosine antibody, then
stripped and reprobed for the receptor tag HA. MCF-10As expressing mutant ErbB2 were stimulated for 30min with 1.0mM AP1510,
lysed and run out on an SDS–polyacrylamide gel electrophoresis gel. Numbers below the phosphotyrosine blot indicate the fold
increase in tyrosine phosphorylation between unstimulated and stimulated samples.
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mature, organized, 3D acini. As expected, activation of
wtErbB2 induced disruption of 3D acinar organization
(Figure 2b, see insert), herein referred to as a multiacinar
structure. As we have reported in the past, MCF-10A
cells expressing ErbB2 have a basal, dimerizer-indepen-
dent, receptor phosphorylation (Figure 1c) and form
multiacinar structures in 3D cultures even in the absence
of small molecule ligand-induced dimerization and
activation (Figure 2c). Activation of wtErbB2 resulted
in 53.9% of multiacinar structures, which was 1.82-fold
higher than that observed in the absence of receptor
activation. All the ErbB2 mutants, except YPD, retain
the ability to induce multiacinar structures in MCF-10A
3D acini. WtErbB2 and all the mutants, except YPD,
were capable of increasing rates of proliferation in the
3D structures (Supplementary Figure 1). Therefore, as
observed in the fibroblast focus-forming assay, each of
the four single tyrosine phosphorylation sites on ErbB2
is capable of inducing morphological disruption of
MCF-10A 3D acini.
Figure 2 Autophosphorylation site mutants transform Rat1 fibroblasts and MCF-10As. (a) Rat1 fibroblasts were transfected on day
1 with 20mg of DNA, stimulated with 1.0 mM AP1510 when the cells were confluent on day 3 and then grown in the presence or absence
of AP1510 for the following 15 days. The plates were then fixed and stained with Giemsa and the foci were counted. Graph represents
four or more experiments for each construct. (b) MCF-10As expressing mutant ErbB2 were plated on matrigel. Structures were grown
for 12 days and then stimulated for 4 days with 1.0mM AP1510. Phase images were taken at day 16. Scale bars represent 50 mm.
(c) Three independent experiments were quantitated to determine the percentage of multiacinar structures in each condition.
**Po0.005, *Po0.05.
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Tyrosine 1201 is sufficient to disrupt apical–basal polarity
ErbB2-induced disruption of acinar organization is
accompanied by a disruption of cell polarity. Although
disruption of cell polarity in MCF-10A 3D acini can be
measured by monitoring localization of the Golgi
apparatus (Aranda et al., 2006), we chose to use another
the epithelial cell line, Madin–Darby canine kidney II
(MDCK II) cells, to directly analyse the effect of ErbB2
activation on disruption of apical–basal polarity.
MDCK II cells are ideal for studying apical–basal cell
polarity because the apical, lateral and apical–lateral
borders can be effectively resolved using markers
such as gp135 (apical), E-cadherin (lateral) and zona
occludens 1 (ZO-1) (apical–lateral border). Our labora-
tory has previously shown that the activation of ErbB2
for 24 h results in mislocalization of tight junctions from
their normal localization at the apical–lateral border in
75% of cells (Aranda et al., 2006).
We generated MDCK II cells expressing the wtErbB2
or the autophosphorylation site mutants. We selected
for cells expressing comparable levels of the receptor
chimera. To limit variability in phenotype due to
differences in expression level of the receptor, we only
examined cells with a defined intensity of anti-HA signal
as determined by ImageJ software (see Materials and
methods section for details). In polarized MDCK cells,
ZO-1 was restricted to a region of the cells that is 2.0 mm
from the apical surface. Activation of ErbB2 induced
mislocalization of ZO-1 to regions that are X3.0 mm
below the apical membrane of the cell. Although
wtErbB2 and all of the autophosphorylation site
mutants were effective in disrupting cell polarity, we
observed a quantitative difference in the extent to which
they induced disruption of tight junctions. Activation of
wtErbB2 induced mislocalization of ZO-1 in B70% of
cells, whereas Y1144, Y1226/7 and Y1253, but not
Y1201, mutants showed significantly lower ZO-1 mis-
localization (52–54%) (Figure 3). The disruption of tight
junctions observed by the activation of the Y1201
mutant was not significantly different from the effect
observed on activation of the wt receptor, suggesting
that Y1201 was as potent as the wt receptor in its ability
to disrupt apical–basal polarity.
ErbB2-induced inhibition of apoptosis is mediated
by Y1226/7
We next investigated whether the ErbB2 autophosphor-
ylation site mutants differ in their ability to inhibit cell
death. Although all the mutants retained the ability to
disrupt acinar structure and induce proliferation, we
noticed that only the activation of Y1226/7 induced
filling of luminal space in 3D acini (Supplementary
Figure 2). We have previously shown that the lumen
formation and maintenance in MCF-10A 3D acini is
regulated by cell death (Debnath et al., 2002). Thus, we
investigated whether ErbB2 uses signals downstream of
the Y1226/7 autophosphorylation site to inhibit apop-
tosis. Activation of wtErbB2 during MCF-10A mor-
phogenesis in 3D blocks activation of caspase-3 in cells
located in the luminal space (Debnath et al., 2002). We
investigated whether activation of the autophosphoryla-
tion site mutants differed in their ability to inhibit
activation of caspase-3. As observed for regulation of
proliferation and polarity readouts, activation of YPD
had no effect in the percentage of acini that stained
positive for activated caspase-3. Interestingly, activation
of Y1226/7 showed a significant decrease in acini with
cells dying in the lumen, whereas, none of the other
mutants showed significant inhibition of apoptosis
(Figures 4a and b). We note that the modest decrease
observed for Y1144, Y1201 and Y1253 mutants did not
reach statistical significance in our experiments (see
Materials and methods section for more details).
The decrease in rates of apoptosis relates to the
presence of filled lumens in 3D acini. We used acini
stained for 4,6-diamidino-2-phenylindole and monitored
the presence or absence of cells in the lumen by optical
sectioning approaches. The activation of wtErbB2 and
Y1226/7 resulted in acinar structures that had lumens
filled with cells, whereas acini derived from the other
mutants did not show a significant increase in percen-
tage of acini with cells in the luminal space (Supple-
mentary Figure 2 and Figure 4c). These results show
that only signals from Y1226/7 were sufficient to inhibit
cell death.
Y1226/7 mediates paclitaxel resistance
Inhibition of apoptosis is particularly important in the
clinic, where it contributes to resistance to cytotoxic
chemotherapies.
We tested the ability of ErbB2 activation in MCF-
10A cells to inhibit the death of cells treated with
various cytotoxic agents. Multiple chemotherapeutic
drugs blocked growth of MCF-10A cells in a dose-
dependent manner (Table 1). Interestingly, short-term
activation of ErbB2 did not protect cells against death
induced by camptothecin, doxorubicin or etoposide
(Supplementary Figure 3), whereas activation blocked
cell death induced by paclitaxel (Figure 5a). Although
previous studies have shown that cells overexpressing
ErbB2 resist death induced by camptothecin, doxorubi-
cin or etoposide (Knuefermann et al., 2003); all those
experiments were carried out using cells that were
selected for high levels of expression of constitutively
active ErbB2. It is likely that long-term activation of the
receptor leads to activation of pathways that are not
direct targets of the ErbB2 receptor, but are activated in
cell populations selected for constitutive ErbB2 signal-
ing. Our results using the inducible MCF-10A cells
suggest that resistance to paclitaxel is mediated by
signaling pathways directly downstream of ErbB2
activation.
To determine whether the signaling pathways down-
stream of the individual tyrosine sites differ in their
ability to inhibit paclitaxel-induced death, we activated
ErbB2 mutants with specific autophoshorylation sites.
Only activation of Y1226/7 inhibited paclitaxel-induced
cell death, whereas activation of YPD, Y1144, Y1201 or
Y1253 was unable to inhibit paclitaxel-induced death.
The inhibition of paclitaxel-induced death was observed
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Figure 3 Y1201 disrupts apical–basal epithelial cell polarity. Madin–Darby canine kidney II cells were grown on transwell filters for 4
days and then stimulated with 1.0 mM AP1510 for 24 h. (a) Immunofluorescent images of the cells depict the tight junction marker zona
occludens 1 (ZO-1) in red. Expression of the receptor is determined by staining the cells for the hemagglutinin (HA) tag, as visualized in
green. The nuclei have been stained blue with 4,6-diamidino-2-phenylindole. Square images, xy views; top and side images, xz views.
Red arrows, plane of xz view that was chosen for the xy view, also represented in the schematic depiction. (b) Three independent
experiments were quantitated to determine the percentage of cells with mislocalized ZO-1 in each condition. **Po0.005.
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over a range of paclitaxel concentrations from 0.05 to
1.0 mM (Figure 5b and data not shown) and was
comparable with the effect observed in response to
activation of wtErbB2 (Figure 5b), suggesting that
Y1226/7 is the principal effector of ErbB2-induced
signals that inhibit apoptosis. Point mutations of ErbB2
that lack one phosphorylation site, leaving the other
phosphorylation site intact, Y1226/7F or Y1253F, still
retained the ability to inhibit cell death (Supplementary
Figure 4), indicating that in the absence of Y1226/7, all
the other sites collectively accomplish what Y1226/7 can
accomplish on its own.
Y1226/7-mediated inhibition of apoptosis is independent
of Erk or Akt activation
ErbB2 signaling activates two main pathways, the Ras/
Erk and the PI3K/Akt pathway (Pupa et al., 2005).
Although the Erk pathway is thought to primarily
promote proliferation, there are some indications that it
can function as a cell survival signal, whereas activation
of Akt pathway inhibits cell death (Wada and Pennin-
ger, 2004; Pupa et al., 2005). Previous studies have
shown that signaling from any of the autophosphoryla-
tion site is sufficient to activate Ras/Erk signaling
(Dankort et al., 2001b); consistent with this observation,
Figure 4 Y1226/7 mediates ErbB2 inhibition of apoptosis in three-dimensional (3D) epithelial structures. MCF-10As expressing
mutant ErbB2 were plated on matrigel. Structures were grown for 12 days and then stimulated for 4 days with 1.0 mM AP1510, fixed
and stained. Immunofluorescent images of 3D structures, in which cells express the indicated ErbB2 mutant are seen in (a). The
apoptotic marker cleaved caspase-3 is visualized in red. The nuclei have been stained blue with 4,6-diamidino-2-phenylindole (DAPI).
Scale bars represent 50 mm. (b) The percentage of acini positive for cleaved caspase-3 was determined in three independent experiments.
(c) The percentage of acini with filled lumen, as determined by acini lacking DAPI staining in the center of structures, was quantitated
in three independent experiments. **Po0.005.
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we find that activation of all ErbB2 mutants induced an
increase in phosphorylation of Erk (Figure 5c). In
addition, all the ErbB2 mutants were able to induce an
increase in phosphorylation of Akt at ser 473, a
surrogate for monitoring activation of the Akt pathway
(Figure 5d). We note that the modest increase in Erk
and Akt phosphorylation observed in YPD is consistent
with the previous observation that YPD still retains the
ability to interact with and activate c-Src tyrosine kinase
(Kim et al., 2005), which in turn can activate down-
stream signaling. Although previous studies have shown
that the activation of Akt signaling regulates inhibition
of cell death pathways downstream of ErbB2 and other
oncogenes (Zhou et al., 2000; Nelson and Fry, 2001), we
did not observe any correlation between Akt activation
and inhibition of paclitaxel-induced death. It is possible
that the amplitude of Akt activation is not high enough
for Akt to induce anti-apoptotic pathways. Consistent
with this possibility, we have previously shown that
ErbB2 homodimers are weaker than ErbB1/ErbB2
heterodimers of EGF ligand in their ability to activate
Akt (Muthuswamy et al., 1999; Zhan et al., 2006).
Table 1 Short-term activation of ErbB2 does not inhibit cell death induced by camptothecin, doxorubicin or etoposide
Paclitaxel
(mM)
Percentage cell
survival
Camptothecin
(mm)
Percentage cell
survival
Doxorubicin
(mm)
Percentage cell
survival
Etoposide
(mm)
Percentage cell
survival
0 100 0 100 0 100 0 100
0.01 89 0.1 93 0.05 78 10 99
0.05 62 0.5 97 0.1 63 100 37
0.1 35 1 89 0.25 71
0.5 27 5 48 0.5 48
1 30 10 9 1 34
MCF-10As expressing inducible ErbB2 were plated at 0.6 106 cells. After 2 days the media was changed with the indicated concentrations of
camptothecin, doxorubicin or etoposide in the presence or absence of 1.0mM AP1510. On day 4, live cells were fixed and stained with crystal violet.
The amount of dye retained, which is a direct measure of live cells, was determined by lysing the cells and quantitating the dye using a
spectrophotometer. The data are represented as percentage decrease in cell survival compared with the untreated control.
Figure 5 Y1226/7 mediates ErbB2 inhibition of paclitaxel-induced apoptosis. (a) Two days after plating MCF-10As, cells were treated
with increasing concentrations of paclitaxel from 0.01 to 1.0mM in the presence or absence of 1.0 mM AP1510. On day 4, cells were
stained with crystal violet and then lysed. Relative amounts of cells survival were calculated after quantitation of the amount of crystal
violet in the cell lysate, using the spectrophotometer. (b) A graph showing the response of cells to activation of the individual
autophosphorylation site mutants in the presence of 0.5 mM taxol (*Po0.05; **Po0.005). (c) MCF-10As were grown to confluency,
serum starved overnight and then stimulated with 1.0mM AP1510 for 10min. The membrane was first blotted for pErk and then
stripped and reprobed for Erk. (d) Lysates were collected under the same conditions, but treated with 1.0mM AP1510 for 1.0 h. The
membrane was first blotted for pAkt and then stripped and reprobed for Akt.
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ErbB2 induced expression of an anti-apoptotic protein,
Mcl-1, which has been shown to regulate cell death
(Henson et al., 2006); however, we did not observe any
decrease in Mcl-1 levels in response to ErbB2 activation
(Supplementary Figure 5). The redundancy with which
ErbB2 activates the Erk and Akt pathways, and the lack
of Mcl-1 protein regulation, suggests that Y1226/7 may
facilitate activation of novel pathways to inhibit cell
death in response to paclitaxel.
Shc was required for ErbB2-mediated resistance
to apoptosis
Y1226/7 is known to bind the signaling adaptor Shc
(Dankort et al., 2001a); however, a recent study using an
in vitro Src homology 2 (SH2) and protein tyrosine-
binding (PTB) domain protein array identified Syk and
Abl2, in addition to Shc, as major binding partners for
the Y1226/7 phosphotyrosine (Jones et al., 2006). The
same study showed that Abl2 SH2 domain also interacts
with Y1144 and Y1253; the Shc SH2 domain can also
interact with Y1144, Y1201 and Y1253, and the Syk SH2
domain with Y1028. The Y1028 site has been identified
as a negative regulatory site, which is consistent with the
observations that Syk functions as a tumor suppressor in
breast cancer (Coopman et al., 2000). The sequence
surrounding Y1226/7 (DNLYYWDQD) conforms best
to the NPXY consensus binding site for the PTB domain
of Shc (Harrison, 1996). Consistent with this possibility,
far-western analysis showed that the Shc-PTB domain,
and not the Shc-SH2 domain, associates with Y1226/
1227 (Dankort et al., 2001a). Coimmunoprecpitation
analysis shows that Shc does not interact with phospho
Y1144, Y1201 and Y1253, whereas it interacts with
Y1226/7 (Figure 5c). It is likely the data obtained from
protein arrays differ from coimmunoprecipitation ana-
lysis in both stringency and sensitivity, and that Y1126/7
is the primary Shc binding site on ErbB2. Recent data
identified a relationship between Shc phosphorylation
and lower rates of apoptosis in polyomavirus middle
T antigen-induced mammary tumors (Ursini-Siegel et al.,
2008). Whether Shc has a role in ErbB2-induced
inhibition of apoptosis is not known.
We hypothesized that the recruitment of Shc to the
ErbB2 receptor is required for Y1226/7-induced inhibi-
tion of apoptosis. Our results show that both wtErbB2
and Y1226/7, but not the other mutants, coimmuno-
precipitated with Shc, showing that activation of ErbB2
recruits Shc through Y1226/7. To rule out the possibility
that Shc phosphorylation (and hence activation of a Shc
pathway) can be induced by sites other than 1226/7, we
analysed changes in Shc phosphorylation in response to
activation of ErbB2 mutants. Both wtErbB2 and Y1226/7
induced an increase in Shc phosphorylation, whereas,
other ErbB2 mutants were not capable of activating Shc
(Figure 6a).
To determine whether Shc is required for Y1226/7-
induced inhibition of cell death, we stably knocked
down Shc expression in Y1226/7 cells using RNA
interference. We generated three short hairpin RNAs
that induced a 6- to 15-fold decrease in the p46 Shc
protein levels, an 8- to 35-fold decrease in the p52 Shc
protein levels, and a 10- to 100-fold decrease in the p66
Shc protein levels in 10A-Y1226/7 cells (Figure 6b).
Y1226/7 is thought to mediate activation of the Erk
pathway by recruiting Shc to the membrane (Dankort
et al., 1997). Therefore, we expected that a functional
Shc knockdown in these cells would decrease Erk
phosphorylation in response to ErbB2–Y1226/7 activa-
tion. Y1226/7 receptor induced phosphorylation of Erk
and Akt was two- to threefold weaker in Shc RNA
interference cells compared with the parental cells,
showing that knockdown of Shc interferes with signal-
ing by ErbB2 (data not shown).
All three Shc knockdown cell populations were
analysed for the effect of Y1226/7 activation-induced
inhibition of paclitaxel-induced cell death (Figure 6c).
Downregulation of Shc inhibited the ability of
Y1226/7 to block cell death showing that Shc has a
critical role during Y1226/7-induced inhibition of
apoptosis.
To determine whether Shc is a critical effector of the
anti-apoptotic signals generated by wtErbB2, we
knocked down Shc in 10A-ErbB2 cells (Figure 7a) and
investigated whether activation of wtErbB2-induced
inhibition of apoptosis in 3D structures requires Shc.
Although the activation of ErbB2 inhibited luminal
apoptosis in control 3D acini, activation of ErbB2 was
not able to inhibit apoptosis in cells knocked down for
Shc expression (Figures 7b and c).
Thus, our results show that ErbB2 uses nonredundant
mechanisms to inhibit cell death by activating an Shc-
dependent signaling pathway.
Discussion
Here we use inducible ErbB2 activation system and 3D
cell culture to better understand ErbB2-induced bio-
logical effects in human mammary epithelial cells. We
show that ErbB2 uses redundant mechanisms to induce
cell proliferation, whereas it is more selective in path-
ways used to disrupt cell polarity and inhibit cell death.
Only activation of Y1201 was as potent as wtErbB2 in
its ability to disrupt apical–basal polarity and only
Y1226/7 is sufficient for the inhibition of cell death. The
ability of Y1226/7 to inhibit cell death required the
signaling adaptor molecule Shc. Although Shc is a
known regulator of cell proliferation pathways, its role
in cell death is not well understood. Thus, we have
identified specific autophosphorylation residues that are
sufficient to trigger cell biological effects relevant to
cancer. In addition, we have defined a novel role for Shc
as a regulator of cell death pathways in ErbB2-mediated
transformation of mammary epithelial cells.
Consistent with previous studies, our results obtained
using inducible ErbB2 autophosphorylation site mu-
tants show that phosphorylation of Y1144, Y1201,
Y1226/7 or Y1253 residues is sufficient to induce cell
proliferation and activate the MAP kinase and Akt
signaling pathways. These observations highlight the
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robustness with which ErbB2 signals to induce cell
proliferation and transform the mammary epithelia. It
also raises caution about developing strategies to target
pathways downstream of ErbB2 that regulates cell
proliferation because it is more likely that ErbB2 will
overcome the inhibition by activating alternate path-
ways to drive cell proliferation.
ErbB2 was selective in its ability to disrupt polarity.
Only activation of Y1201 phenocopied wtErbB2; how-
ever, Y1144, Y1226/7 and Y1253 are all capable of
inducing a partial disruption of polarity (Figure 3). We
have recently shown that ErbB2 requires an interaction
with Par6/aPKC, a polarity complex to disrupt cell
polarity (Aranda et al., 2006). Consistent with partial to
complete disruption of polarity, we find that all the
autophosphorylation sites retain the capacity to interact
with Par6/aPKC (data not shown). Interestingly, ErbB2
also requires the Src kinase to disrupt polarity in
MDCK cells (Kim et al., 2005). Src interacts with the
kinase domain of ErbB2, similar to Tyr 882 within the
activation loop (Kim et al., 2005). This tyrosine is intact
in all of the autophosphorylation mutants used in
this study and can thus explain the ability of Y1144,
Y1226/7 and Y1253 mutants to disrupt polarity.
However, except Y1201, activation of other tyrosine
residues resulted in a partial effect, suggesting that
Y1201 has unique properties in addition to interacting
with Src. Y1201 is known to recruit CrkII and Nck, the
known substrates of Src kinase and regulators of the
cytoskeleton (Dankort et al., 1997; Dankort and Muller,
2000; Feller, 2001; Buday et al., 2002), raising the
possibility that, in addition to interacting with Src,
recruitment of Src-specific substrate(s) to the proximity
of the receptor is necessary to induce a complete
disruption of polarity. Further analysis will be necessary
to test this hypothesis.
Recent studies show that pathways downstream
of Y1226/7 are also sufficient to induce migration
(Marone et al., 2004) and neovasculogenesis (Saucier
et al., 2004). Our results, together with these observa-
tions suggest that among the signaling pathways
activated by ErbB2, those that are downstream of
Y1226/7 uniquely regulate biological processes relevant
to cell transformation and offer an opportunity for
therapeutic intervention.
It is likely that understanding how Shc regulates cell
death pathways will offer new therapeutic opportunities
for controlling paclitaxel resistance. Our results suggest
that the Shc-mediated inhibition of apoptosis is in-
dependent of activation of the Ras/MAPK signaling
pathways because all ErbB2 autophosphorylation site
mutants retain the ability to activate Ras/MAPK
Figure 6 Y1226/7-mediated inhibition of apoptosis. (a) MCF-10As were grown to confluency, serum starved overnight and then
stimulated with 1.0mm AP1510 for 1.0 h. Shc was immunoprecipitated. The membrane was blotted for phospho-tyrosine and then
stripped and reprobed for Shc. (b) Western blot showing stable Shc knockdown in MCF-10A cells using short hairpins. Expression
levels were normalized to actin. (c) A cell survival assay as described in Figure 5 was performed using these cells. The results of three
independent experiments are shown in the graph (*Po0.05).
ErbB2 requires Shc to block apoptosis in epithelial cells
AV Lucs et al
183
Oncogene
ErbB2 requires Shc to block apoptosis in epithelial cells
AV Lucs et al
184
Oncogene
signaling (Figures 5c and d) but lack the ability to
inhibit cell death (Figures 4 and 5b). Most known
mechanisms of paclitaxel resistance depend on altering
the dynamics of the microtubule polymerization (Orr
et al., 2003). Shc can regulate microtubule dynamics by
at least three independent mechanisms. Shc interacts
with SHIP-2 (Habib et al., 1998), which has recently
been shown to deter microtubule stabilization in mast
cells (Leung and Bolland, 2007). It is possible that the
Shc–SHIP-2 interaction leads to destabilization of
microtubules. Shc has also been shown to interact
directly with actin in PC12 cells (Thomas et al., 1995)
and to cause reorganization of the cytoskeleton (Gu
et al., 1999). As changes in the actin cytoskeleton can
increase resistance to anti-microtubule drugs (Verrills
et al., 2006), it is possible that the interaction of Shc with
the actin cytoskeleton mediates resistance to taxol.
Finally, the mediator of ErbB2-driven cell motility,
which binds to the Y1226/7 of ErbB2, possibly through
Shc, is necessary for ErbB2-induced microtubule poly-
merization in T47D and SkBr3 cells (Marone et al.,
2004). It is also possible that Shc activates general anti-
apoptotic pathways, such as upregulation of Bcl-2, Bfl-1
or downregulation of BH3 proteins, Bim, consistent
with previous studies in which overexpression of Bcl-2
has been shown to inhibit apoptosis in 3D structures
(Debnath et al., 2002). Interestingly, a recent study
showed that the expression of a phosphorylation site
mutant version of Shc (Y313F) increases cell death in a
polyomavirus mT mouse model of mammary tumor-
igenesis, suggesting that the ability of Shc to regulate cell
survival pathways is not limited to ErbB2-dependent
tumors (Ursini-Siegel et al., 2008). A deeper analysis to
understand how Shc signals to inhibit paclitaxel-induced
cell death is likely to have broad clinical benefit.
Resistance to ErbB2-directed therapies in multiple
clinical settings highlights the need to develop alter-
native treatment paradigms for ErbB2-positive tumors.
Our results suggest that inhibiting cell death pathways,
and not cell proliferation pathways, downstream of
ErbB2 as a potentially effective therapeutic strategy as
ErbB2 uses nonredundant mechanisms to inhibit cell
death. Understanding the pathways downstream of the
ErbB2–Shc interaction may not only identify novel
combination drug targets but also identify biomarkers
for predicting response to chemotherapies.
Materials and methods
Cloning of autophosphorylation site mutants
The individual autophosphorylated tyrosine sites were mu-
tated one tyrosine at a time to phenylalanine using the
Quickchange kit (Stratagene, La Jolla, CA, USA). The
constructs were generated in Neu, the rat homolog of human
ErbB2, intracellular domain with silent mutations abolishing
the Xba restriction sites in a pCG backbone. After sequence
verification, the ErbB2 intracellular domain was PCR ampli-
fied, purified, digested with Xba1/Spe1 and ligated to the
retroviral vector pBabe.p75.F2.HA as previously described
(Muthuswamy et al., 1999) at the Spe1 locus.
The primers used to generate the tyrosine to phenylalanine
mutations were as follows: 50-Y1028 GTAGACGCTGAA
GAATTCCTGGTGCCCCAG, 30-Y1028 CTGGGGCACC
AGGAATTCTTCAGCGTCTAC, 50-Y1144AGCCCCCAG
CCCGAATTTGTGAACCAATCA, 30-Y1144 TGATTGGT
TCACAAATTCGGGCTGGGGGCT, 50-Y1201 GTGGAG
AACCCTGAATTCTTAGTACCGAGA, 30-Y1201 TCTC
GGTACTAAGAATTCAGGGTTCTCCAC, 50-Y1226/7 TT
TGACAACCTCTTCTTCTGGGACCAGACC, 30-Y1226/7 GG
TCTGGTCCCAGAAGAAGAGGTTGTCAAA, 50-Y1253 GA
GAACCCTGAGTTCCTAGGCCTGGAT, 30-Y1253 ATCC
AGGCCTAGGAACTCAGGGTTCTC.
Cell culture
MCF-10A cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM)/F12 (Gibco, Invitrogen, Carlsbad,
CA, USA), 5% horse serum (Hyclone, Waltham, MA, USA),
1% penicillin/streptomycin (Gibco), 100 ng/ml cholera toxin,
10 mg/ml insulin, 500 ng/ml hydromycin (Sigma, St Louis, MO,
USA) and 20 ng/ml EGF (Peprotech, Rocky Hill, NJ, USA).
Assay media used for 3D studies was made of DMEM/F12,
2% horse serum, 1% penicillin/streptomycin, 100 ng/ml
cholera toxin, 10mg/ml insulin and 500 ng/ml hydromycin.
MDCKs and Rat1 fibroblasts were grown in DMEM (Gibco),
10% fetal bovine serum and 1% penicillin/streptomycin.
Focus-forming assay
Rat1 fibroblasts were plated at 2 105 cells per 6-cm dish on
day 0. On the next morning, cells were transfected with 10mg
pBabe p75.F2.ErbB2.HA and pBabe p75.F2.8A.HA using
calcium phosphate. At 6 h after transfection, cells were washed
twice with DMEM/0.5% fetal bovine serum and then
incubated overnight in DMEM/10% fetal bovine serum. On
day 2 the media was changed. By day 4 cells had become
confluent and cells were stimulated by changing the media and
adding 1.0mM AP1510 (Ariad Pharmaceuticals, Cambridge,
MA, USA). Media was changed every 3 days until day 16,
when cells were fixed with 4% PFA and stained with Giemsa.
Fluorescence-activated cell sorting
MCF-10A cells expressing the chimeric receptor were dis-
sociated by incubation at 37 1C with 10mM EDTA:0.25%
trypsin:phosphate-buffered saline for 30min. The cells were
then collected and washed twice in growth media. In all,
15 106 cells were resuspended in 3ml of media and incubated
for 30min with the p75 NGFR antibody. Cells were washed
three times with fresh media, resuspended in 1.5ml media with
15 ml of anti-mouse 488 antibody and incubated at room
temperature for 1.0 h before washing again three times in
Figure 7 Shc is necessary for ErbB2-induced inhibition of apoptosis in three-dimensional (3D) epithelial structures. (a) Western blot
showing stable Shc knockdown in MCF-10A cells using short hairpins. Actin is shown as a loading control. (b) MCF-10A-ErbB2 cells
were plated on matrigel. Structures were grown for 4 days and then stimulated for 4 days with 1.0mM AP1510, fixed and stained.
Immunofluorescence images of 3D structures stained with an apoptotic marker-cleaved –caspase-3 is shown. The nuclei are stained
blue with 4,6-diamidino-2-phenylindole. Scale bars represent 100 and 50 mm in inset. (c) The percentage of acini positive for cleaved
caspase-3 was determined for three independent experiments. *Pp0.05.
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growth media. After the final wash cells were resuspended in
3.0ml of growth media, filtered through a 3.5-mm mesh and
run on the FACSVantage SE Cell Sorter (BD Biosciences, San
Jose, CA, USA). The population of positive staining cells was
divided into low, medium and high expressing groups,
collected and returned to culture. Medium level expressing
cells were used for further experiments.
3D assays
A total of 4000 cells were plated per well of an eight chamber
slide coated with 70ml matrigel in assay media containing
2.5% matrigel and 5 ng/ml EGF. Cells were cultured for 16
days, changing media every 4 days and stimulating with 1.0 mM
AP1510 on day 12. Phase images on cells were taken every 4
days. After imaging on day 16, slides were fixed in 4% PFA,
permeabilized in 0.5% Triton and incubated with the
antibodies indicated for immunofluorescence.
MDCK polarity assay
Madin–Darby canine kidney II cells were plated on 12-well
transwell filters at 0.5 106 cells per well and grown for 4 days,
at which point cells were stimulated with 1 mM AP1510. After
24 h of stimulation, cells were fixed in 4% PFA, permeabilized
in 0.2% Triton and incubated with the antibodies indicated for
immunofluorescence. Images were all taken with preset
exposure times. Cells that expressed HA at a level between
10 and 100 units of intensity according to ImageJ software
were analysed for mislocalization of ZO-1.
Cell survival assay
MCF-10A cells expressing the mutants were plated at 0.6 106
cells per well of a six-well plate in growth media. Two days
after plating, the media was replaced again with growth media
þ / taxol in varying concentrations and ±1.0mM AP1510.
After 2 days in the presence or absence of drugs, the plates
were washed three times in phosphate-buffered saline, fixed
with a crystal violet solution (0.25% crystal violet in 20%
methanol) for 10min, washed six times in water and incubated
in 700 ml lysis solution (51% water, 48% ethanol, 1% HCl) for
1 h. To quantitate the amount of crystal violet in each sample,
25 ml of the lysate was diluted in 975ml of water, mixed and the
optical density at 600 nm was determined using the spectro-
photometer. Percent survival was calculated using the un-
treated condition as the denominator.
Antibodies
The HA antibody was obtained from Covance (Berkley, CA,
USA), actin from Sigma, Ki67 from Zymed Laboratories
(San Francisco, CA, USA) and NFGR from Chromoprobe
(Maryland Heights, MO, USA). The Shc, phospho-tyrosine
pY20 and Erk2 antibodies were all obtained from BD
Transduction Laboratories (San Jose, CA, USA). Phospho-
Ser 473-Akt, Akt, cleaved caspase-3 and phospho-p44/
42MAPK were all from Cell Signaling (Danvers, MA, USA).
Quantitation of blots was carried out with ImageJ (NIH) blot
analysis.
Statistics
All statistics were performed using a standard Student’s t-test.
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